Sysmex Inostics, Inc., a US-based Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators with ultra-sensitive, quantitative, and cost-effective CLIA-validated SafeSEQ NGS liquid biopsy services. SafeSEQ is optimized to ensure the detection of low-frequency mutant molecules (<0.03% MAF) without sacrificing specificity.